Eli Lilly and Co. (NYSE:LLY) shares were little changed in Monday’s premarket session. The U.S. drug giant shared results from the Phase 3 BRUIN CLL-322 trial of Jaypirca (pirtobrutinib), which showed...
Source Link- Like
- Comment
- Favorite
Eli Lilly's Jaypirca Builds Case With Fourth Positive Phase 3 Trial In Blood Cancer Patients
Benzinga_recent_news04-13 21:29
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Like
Report
Login to post
No comments yet